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tus, and ethnicity were associated with lower cognition. 
 Conclusions: At 2 years, most CDH patients have normal 
cognition, but are at risk for motor function delay. Due to 
differences in outcomes between centers, careful interpre-
tation is needed before conclusions can be drawn for other 
centers. Future multicenter collaboration should not only 
focus on standardization of postnatal care, but also on in-
ternational standardization of follow-up to identify risk fac-
tors and thereby reduce morbidity.  © 2015 S. Karger AG, Basel 
 Introduction 
 Congenital diaphragmatic hernia (CDH) affects ap-
proximately 1 in 3,000 newborns  [1] . It is a life-threaten-
ing disease caused mainly by persistent pulmonary hy-
pertension and pulmonary hypoplasia  [1] . Severely ill 
CDH patients may receive extracorporeal membrane ox-
ygenation (ECMO)  [1] . In 2008, a standardized neonatal 
treatment protocol was developed at a consensus meeting 
of the CDH EURO Consortium  [1] . The mortality rate 
has decreased from 33 to 12% since this protocol was im-
plemented  [2] . Consequently, worldwide the focus of in-
terest has shifted to morbidity  [3–5] . 
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 Abstract 
 Background: Since mortality in congenital diaphragmatic 
hernia (CDH) is decreasing, morbidity such as neurodevel-
opmental outcome is becoming increasingly important. 
 Objectives: We evaluated neurodevelopmental outcome in 
high-risk CDH patients treated according to the CDH EURO 
Consortium standardized treatment protocol.  Methods: 
This observational, prospective cohort study was conduct-
ed in two European centers. Neurodevelopment of 88 pa-
tients (Rotterdam n = 49; Rome n = 39) was assessed at 12 
and 24 months with the Bayley Scales of Infant Develop-
ment (BSID)-II-NL (Rotterdam) or BSID-III (Rome). Data of the 
centers were analyzed separately.  Results: Cognition was 
normal in 77.8% of children from Rotterdam and in 94.8% 
from Rome at 12 months, and in 70.7 and 97.4%, respec-
tively, at 24 months. Motor function was normal in 64.3% 
from Rotterdam and in 81.6% from Rome at 12 months and 
in 45.7 and 89.8%, respectively, at 24 months. Longer length 
of hospital stay (LoS) was associated with worse cognitive 
outcome and motor function; LoS, low socioeconomic sta-
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 Previous studies found associated morbidity in about 
87% of CDH survivors, mainly related to the lungs or the 
gastrointestinal tract  [6, 7] . While most follow-up studies 
have focused on morbidity, few have examined neurode-
velopment. Most of those studies were cross-sectionally 
performed in small series in single centers  [8–10] . Re-
cently, longitudinal studies have shown neurodevelop-
mental delays in CDH patients  [3, 4, 11] . To date, no pub-
lished studies have examined neurodevelopmental out-
come after implementation of a standardized treatment 
protocol in a multicenter setting. 
 We longitudinally investigated neurodevelopmental 
outcome in high-risk patients managed according to the 
CDH EURO Consortium standardized treatment proto-
col  [1] in two high-volume CDH centers. Secondly, we 
identified determinants of neurodevelopmental outcome. 
 Materials and Methods 
 This is an observational, prospective cohort study in patients 
born between January 2009 and May 2012 with high-risk CDH, i.e. 
antenatal diagnosis/respiratory insufficiency within 6 h postnatal-
Cognition and motor function
assessed: n = 40
Assessment of cognition only: n = 1
Organizational reason: n = 1
Assessment of motor function only: 
n = 6
Noncooperative: n = 5
Organizational reason: n = 1
No developmental assessment: n = 2
Died: n = 1
Refusal: n = 1
Assessment at 24 months
Cognition and motor function
assessed: n = 38
Assessment of cognition only: NA
Assessment of motor function only: 
NA
No developmental assessment: n = 1
Organizational: n = 1
Assessment at 12 months
Cognition and motor function
assessed: n = 39
Assessment at 24 months
Cognition and motor function
assessed: n = 42
Assessment of cognition only: n = 3
Organizational reason: n = 3
Assessment of motor function only: 
NA
No developmental assessment: n = 4
Refusal: n = 2
Organizational: n = 2
Assessment at 12 months
Follow-up Rotterdam
n = 49 (92.5%)
Follow-up Rome
n = 39 (86.7%)
No follow-up assessment at all
Rotterdam Rome
n = 1
n = 2
n = 1
NA
NA
Lost to follow-up
Refusal
Follow-up elsewhere
Organizational reasons
Organizational at 12 months and
not cooperative at 24 months  
n = 2
n = 2
NA
n = 1
n = 1
Eligible for follow-up
n = 98 (69.5%)
Rotterdam
n = 53
Rome
n = 45
Rome
n = 65
Children born between 
January 2009 and May 2012
n = 141
Rotterdam
n = 76
Excluded (reason: died)
Rome n = 19 (29.2%)Rotterdam n = 19 (25.0%)
12 ECMO patients (63.2%)
Excluded (reason: not high-risk patient)
Rome n = 1 (1.5%)Rotterdam n = 4 (5.3%)
 Fig. 1. Flowchart of inclusion of all patients. NA = Not applicable. 
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ly. All patients were treated according to a standardized treatment 
protocol  [1] ; however, ECMO was only offered in Rotterdam. Rot-
terdam and Rome are two of the largest European CDH centers. 
As standard of care, survivors were offered a structured, longitu-
dinal follow-up program, initiated in Rotterdam in 1999  [11] and 
in Rome in 2004  [12] . We evaluated prospectively collected data of 
repeated measurements at corrected ages of 12 and 24 months. 
Since subjects were not submitted to any handling and no rules of 
human behavior were imposed, institutional review board approv-
al was waived. Parents were informed that data were used for re-
search purposes.
 Patient characteristics were retrieved from medical records. 
Neurodevelopmental outcome was assessed with the Bayley Scales 
of Infant Development (BSID). In Rotterdam, the Dutch-language 
version of the BSID-II (BSID-II-NL) was administered with Dutch 
normative data  [13] . In both centers cognitive development was 
assessed at both time points (by two developmental psychologists 
per center). Psychomotor development was assessed by develop-
mental psychologists at both time points in Rome and at 12 months 
in Rotterdam. In Rotterdam, psychomotor development was as-
sessed by one physiotherapist at 24 months. In Rome, the Italian 
translation of the BSID-III  [14] with American normative data was 
administered. Scores were grouped as normal (>–1 SD), mildly 
delayed (–2 < SD <–1) and severely delayed (<–2 SD). For further 
details, see the supplementary file Methods (for all suppl. material, 
see www.karger.com/doi/10.1159/000438978). 
 Data Analysis 
 Descriptive statistics are presented as number (%), mean (SD) 
or median (range). Independent samples t tests, χ 2 tests and Mann-
Whitney U tests, where appropriate, were used to compare char-
acteristics between centers. One-sample t tests served to compare 
mean scores to the normalized population mean. Linear mixed 
models were used to estimate neurodevelopmental outcome over 
time. These models included only the time point (12 or 24 months) 
as the independent variable, and a random intercept to account for 
the within-subject correlations. Perinatal factors associated with 
adverse neurodevelopment were determined using multivariate 
linear regression. Cognition and motor outcome were chosen as 
dependent variables in two different models; the data were ana-
lyzed separately for each assessment, age and each center. Based on 
clinical experience and the literature, the following independent 
variables were included in the linear regression analysis: tube feed-
ing at discharge, ECMO support, ethnicity and SES as categorical 
variables, and SNAP-II score and length of hospital stay (LoS; log-
transformed due to skewed distribution) as continuous variables. 
Analyses were performed using SPSS version 20. 
 Results 
 In the study period, 141 CDH patients were admitted 
(Rotterdam n = 76; Rome n = 65). Thirty-eight children 
died (Rotterdam n = 19; Rome n = 19) and 5 were not 
high-risk CDH patients; thus, 98 children were eligible 
for follow-up. Ultimately, 88 patients were assessed 
( fig. 1 ).
 Baseline characteristics of participants ( table 1 ) were 
not significantly different from nonparticipants. Four pa-
tients (Rotterdam n = 1; Rome n = 3) underwent feto-
scopic endotracheal occlusion. In Rotterdam, 28 patients 
underwent thoracoscopic repair and 7 were converted to 
laparotomy. In Rome, all children underwent laparoto-
my. None of the children received anticonvulsants. Six 
patients from Rotterdam had a genetic or chromosomal 
abnormality that was not associated with neurodevelop-
ment. Patch repair, episodes of general anesthesia 0–24 
months, and involvement of a physical therapist and 
speech-language pathologist were significantly different 
0
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 Fig. 2. Neurodevelopmental outcome in CDH survivors at 12 and 
24 months. Black: Rotterdam; grey: Rome. 
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between Rotterdam and Rome ( table 1 ). After exclusion 
of ECMO-treated patients (online suppl. table 1a), epi-
sodes of general anesthesia 0–24 months and involve-
ment of physical therapy were not significantly different 
between the two centers (online supplementary table 1b).
 Based on the cutoff scores from the BSID manuals, 
cognition was normal in 71 children (85.5%) and motor 
function was normal in 58 children (72.5%) at 12 months; 
this held true for 67 patients (83.8%) and 56 patients 
(65.9%), respectively, at 24 months. Proportions of mild 
and severe neurodevelopmental delay are shown in  figure 
2 .  Table 2 shows means (SD) of neurodevelopmental out-
come. In online supplementary figure 2a and online sup-
plementary table 2a, data were presented after exclusion 
of ECMO-treated patients. 
 In Rotterdam, cognition and motor function remained 
stable over time. In Rome, cognition and motor function 
improved over time [mean differences 4.1 (p = 0.02) and 
5.8 (p = 0.003), respectively]. 
 Table 1. Background characteristics
Rotterdam 
(n = 49)
Rome
(n = 39)
p value1
Perinatal and postnatal characteristics
LHR 1.9 (0.8) 2.2 (0.8) 0.32
Missing 15 13
O/E LHR 51.6 (17.4) 53.3 (15.8) 0.71
Missing 21 13
Male sex 28 (57.1%) 25 (64.1%) 0.51
Birth weight, kg 3.07 (0.56) 2.99 (0.41) 0.45
Born before 37 weeks of
gestation 8 (16.3%) 4 (10.3%) 0.41
SNAP-II score 18 (12) 13 (9) 0.07
Age at repair, days 3.8 (2.7) 3.6 (2.1) 0.77
Left-sided CDH 42 (85.7%) 38 (97.4%) 0.06
Liver: intrathoracic 19 (38.8%) 12 (30.8%) 0.44
Defect size 0.24
A 5 (10.2%) 4 (10.3%)
B 18 (26.7%) 22 (56.4%)
C 24 (49.0%) 11 (28.2%)
D 2 (4.1%) 2 (5.1%)
Patch repair 35 (71.4%) 11 (28.2%) <0.001
Defect size A n = 1 n = 0
Defect size B n = 8 n = 1
Defect size C n = 24 n = 8
Defect size D n = 2 n = 2
Initial ventilation 0.83
CMV 24 (49.0%) 20 (51.3%)
HFO 25 (51.0%) 19 (48.7%)
Length of ventilation, days 8 (1 – 271) 8 (2 – 70) 0.55
Length of initial hospital 
stay, days 28 (6 – 387) 30 (15 – 161) 0.54
CLD 0.12
No CLD 29 (59.2%) 32 (82.1%)
Mild CLD 8 (16.3%) 2 (5.1%)
Moderate CLD 1 (2.0%) 0 (0%)
Severe CLD 11 (22.4%) 5 (12.8%)
Rotterdam 
(n = 49)
Rome
(n = 39)
p value1
Length of morphinomimetics/sedatives 0.28
<1 week 25 (51.0%) 14 (35.9%)
1 week to 1 month 17 (34.7%) 20 (51.3%)
>1 month 7 (14.3%) 5 (12.8%)
Episodes of general 
anesthesia 0 – 24 months 2 (1 – 13) 1 (1 – 3) 0.01
At discharge
Tube feeding 29 (59.2%) 20 (51.3%) 0.46
Physical therapy at home 20 (40.8%) 7 (17.9%) 0.02
Speech language pathologist 
involved 19 (38.8%) 3 (7.7%) 0.001
Demographic variables
Ethnicity 0.13
Native 34 (69.4%) 33 (84.6%)
Nonnative 14 (28.6%) 6 (15.4%)
Unknown 1 (2.0%) 0 (0%)
SES mother 0.12
Low 13 (26.5%) 9 (23.1%)
Medium 15 (30.6%) 21 (53.8%)
High 18 (36.7%) 9 (23.1%)
Unknown 3 (6.1%) 0 (0%)
Categorical variables are shown as n (%) and compared be-
tween centers using χ2 tests, normally distributed variables are 
shown as means (SD) and compared between groups using inde-
pendent samples t tests, and continuous variables that are not nor-
mally distributed are shown as medians (range) and compared be-
tween centers using Mann-Whitney U tests. LHR = Lung-head 
ratio [15]; O/E LHR = observed to expected lung-head ratio; 
SNAP-II score = Score for Neonatal Acute Physiology-II [16]; 
CMV = conventional mechanical ventilation; HFO = high-fre-
quency oscillation; CLD = chronic lung disease [17]; SES = socio-
economic status [18]. 1 Comparison between Rotterdam and 
Rome.
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 In Rotterdam, cognitive outcome at 24 months was 
negatively associated with low socioeconomic status 
(SES) (B –36.2; 95% CI: –58.1 to –14.3) and non-Dutch 
ethnicity (B 25.1; 95% CI: 5.9 to 44.2;  table 3 ). Motor 
function was negatively associated with longer LoS at 24 
months (B –7.8; 95% CI: –15.3 to –0.3). For example, 
taking into account the logarithmic transformation of 
LoS, children who were hospitalized twice as long scored 
5.4 points lower (calculation: B × ln2 = –7.8 × ln2) on 
motor function at 24 months. In non-ECMO-treated 
patients, the SNAP-II score was significantly associated 
with cognition and motor function at 12 months. At 24 
months, low SES and non-Dutch ethnicity were associ-
ated with poor cognition, and low SES and LoS were as-
sociated with poor motor function (online suppl. ta-
ble 3a). In Rome, longer LoS was significantly associated 
with cognition at 12 months (B –13.7; 95% CI: –21.2 to 
–6.2) and 24 months (B –10.2; 95% CI: –20.0 to –0.4), 
and longer LoS and motor function at 12 months 
(B –9.5; 95% CI: –17.7 to –1.4) and 24 months (B –16.7; 
95% CI: –25.1 to –8.2). 
 Discussion 
 This longitudinal study was performed in two Euro-
pean high-volume centers that use the same neonatal 
treatment protocol  [1] in high-risk CDH patients. We 
found normal cognition in 78% of children aged 12 
months in Rotterdam and 95% in Rome. At 24 months 
this was 71% in Rotterdam and 97% in Rome. Normal 
development of motor function occurred in 64% in Rot-
terdam and 82% in Rome at 12 months. At 24 months, 
this was 46% in Rotterdam and 90% in Rome. 
 A few cross-sectional studies have reported neurode-
velopmental outcome in CDH patients  [8–10, 19] . Dan-
zer et al. [9] reported delayed cognition in 32% of 41 
children, assessed with BSID-II or BSID-III at a median 
age of 24 months, and 24% of 42 prospectively enrolled 
patients at 2–4 years assessed with BSID-III  [8] . The 
prevalence of cognitive problems using similar outcome 
categories was comparable for Rotterdam, whilst fewer 
patients in Rome had cognitive delays. It is possible that 
patients in the study by Danzer et al. [8] were more se-
verely ill since they were ventilated longer and more in-
fants received ECMO. In a multicenter study by Wynn 
et al. [19] , mean cognitive scores – obtained with BSID-
III in 48 CDH patients at 24 months – were significant-
ly below normal (mean 93; SD 15). We found the same 
trend; although different BSID versions were applied, 
results from Rotterdam are comparable and results 
from Rome are better. Many factors may contribute to 
cognitive delay in CDH. Consistent with previous stud-
ies, low SES was a significant determinant of cognitive 
delay  [19] . Previously reported predictive factors, such 
as tube feeding at discharge and ECMO need  [19] , were 
not confirmed in our study. However, failure to reach 
statistical significance for ECMO need may have been 
due to the fact that 6 survivors needed ECMO treat-
ment. 
 In general, impaired motor function is more frequent 
than cognitive problems in CDH. Our results on motor 
function were more favorable than those of Danzer et al. 
[9] , who reported mild (23%) and severe (31%) delay on 
 Table 2. Neurodevelopmental outcome scores at 12 and 24 months (corrected for prematurity)
12 months  24 months
Rotterdam1 p
value2
Rome
(n = 38)
p 
value2
Rotter dam3 p
value2
Rome
(n = 39)
p 
value2
Cognitive outcome4 97.8 (19.8) 0.46 97.9 (11.8) 0.28 96.0 (18.4) 0.17 102.1 (13.9) 0.36
Motor outcome4 87.7 (18.8) <0.001 93.2 (12.2) 0.002 82.9 (16.7) <0.001 98.2 (14.8) 0.45
Language outcome4 – – 97.7 (8.6) 0.10 – – 97.7 (12.6) 0.26
Receptive language5 – – 9.4 (1.7) 0.04 – – 10.2 (2.4) 0.60
Expressive language5 – – 9.8 (1.9) 0.51 – – 8.9 (2.5) 0.01
Fine motor skills5 – – 10.1 (2.1) 0.76 – – 10.5 (2.6) 0.23
Gross motor skills5 – – 7.7 (2.5) <0.001 – – 8.9 (2.7) 0.01
1 Cognitive outcome: n = 45; motor outcome: n = 42. 2 Outcome scores were compared to the expected normal score of reference 
population; Rotterdam: BSID-II-NL; Rome: BSID-III. 3 Cognitive outcome: n = 41; motor outcome: n = 46. 4 Mean (SD) of expected 
normal score of reference population is 100 (15). 5 Mean (SD) of expected normal score of reference population is 10 (3). 
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motor function at 24 months. Friedman et al.  [3] re-
ported motor problems in 60% at 1 year and 73% at 3 
years. They retrospectively evaluated medical records 
documenting motor function. It is conceivable that 
standardized developmental assessment would have 
given other outcomes. On the other hand, Wynn et al. 
 [19] found that motor function at 24 months was sig-
nificantly lower than the population norm (mean 95; SD 
11), which is comparable to Rome. Scores in Rotterdam, 
however, were on average 12 points lower. We could not 
confirm their results of adverse motor function in pa-
tients with low SES, but could confirm the result of an-
other study  [4] that LoS was associated with poorer mo-
tor function. 
 Table 3. Determinants of impaired neurodevelopmental outcome; results of linear regression models
Independent variables Rotterdam  Rome
Parameter
estimate
95% CI Para meter 
estimate
95% CI
Cognition
at 12 months
SNAP-II score 0.5 – 0.2 to 1.2 0.1 – 0.0 to 0.33
ECMO 2.3 –25.8 to 30.3 – –
Length of hospital stay, days1 – 9.6 –20.0 to 0.7 –13.7 –21.2 to –6.2
Tube feeding at discharge – 0.2 –19.2 to 19.0 – 1.9 –10.6 to 6.8
Ethnicity 13.3 – 7.7 to 34.3 1.5 – 8.1 to 11.1
SES mother
Low –11.5 –34.9 to 11.9 1.9 – 8.4 to 12.1
Medium 4.6 –16.1 to 25.2 1.2 – 7.7 to 10.1
High2 – – – –
Cognition
at 24 months
SNAP-II score 0.1 – 0.4 to 0.5 0.0 – 0.2 to 0.3
ECMO 20.8 – 9.0 to 50.6 – –
Length of hospital stay, days1 – 5.8 –14.1 to 2.6 –10.2 –20.0 to –0.4
Tube feeding at discharge – 3.5 –18.4 to 11.3 – 4.1 –16.2 to 8.0
Ethnicity 25.1 5.9 to 44.2 – 2.1 –15.5 to 11.4
SES mother
Low –36.2 –58.1 to –14.3 – 7.0 –21.3 to 7.4
Medium –11.5 –27.9 to 4.8 – 3.6 –16.0 to 8.7
High2 – – – –
Motor function
at 12 months
SNAP-II score 0.6 – 0.0 to 1.2 0.0 – 0.2 to 0.2
ECMO 5.6 –22.3 to 33.5 – –
Length of hospital stay, days1 –10.5 –21.6 to 0.5 –9.5 –17.7 to –1.4
Tube feeding at discharge – 0.2 –18.4 to 17.9 –6.6 –16.1 to 2.8
Ethnicity 15.3 – 5.6 to 36.3 3.6 – 6.8 to 14.1
SES mother
Low – 0.8 –23.2 to 21.6 –3.1 –14.2 to 8.1
Medium 1.2 –18.8 to 21.2 –2.4 –12.1 to 7.3
High2 – – – –
Motor function
at 24 months
SNAP-II score 0.3 – 0.2 to 0.8 0.1 – 0.2 to 0.3
ECMO 14.4 – 7.8 to 36.6 – –
Length of hospital stay, days1 – 7.8 –15.3 to –0.3 –16.7 –25.1 to –8.2
Tube feeding at discharge 3.0 –11.0 to 17.0 0.8 – 9.7 to 11.3
Ethnicity 6.2 – 7.4 to 19.9 2.1 – 9.5 to 13.7
SES mother
Low –15.4 –32.1 to 1.4 – 0.2 –12.7 to 12.2
Medium – 2.7 –17.2 to 11.8 5.5 – 5.2 to 16.2
High2 – – – –
SNAP-II score = Score for Neonatal Acute Physiology II. 1 Because of skewed distribution, these variables 
were log-transformed before including them into the linear regression model. 2 Reference category.
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 The strengths of our study were that children were 
treated according to a standardized protocol  [1] and fol-
lowed in a prospective, longitudinal, standardized follow-
up program. We collected data on ethnicity and SES, 
which are well-known modifiers of neurodevelopmental 
outcome  [19] .
 Neurodevelopmental outcomes were different be-
tween the centers, and changes between the two measure-
ment moments were only seen in Rome. We suggest three 
possible reasons. The first is the use of different assess-
ment instruments. Since recent studies reported that 
BSID-II and BSID-III are not comparable  [20] , we re-
frained from pooling the data  [1] . In the transition from 
BSID-II to BSID-III, 23 items from the BSID-II mental 
scale were moved to the BSID-III fine motor scale. Thus, 
with a higher proportion of items in the fine motor func-
tion domain in BSID-III compared to BSID-II (48 vs. 
28%, respectively) the fine motor score contributes rela-
tively much to the total motor composite score in BSID-
III. This is reflected by the fact that in Rome gross motor 
scores are lower than fine motor scores at both ages. We 
assume that the outcome for patients who have a devel-
opmental delay in both cognition and motor function will 
not be very different for the two BSID versions. However, 
results may differ for patients with CDH, who will typi-
cally show impaired motor function. Moreover, recent 
studies showed differences in reference scores of BSID-III 
between populations  [21, 22] . These considerations pos-
sibly explain the underestimation of neurodevelopmental 
delay in Rome. We have few standardized neurodevelop-
mental tests with population-matched reference data and 
the best option seems to compare neurodevelopmental 
outcome with healthy reference populations in each 
country. The use of American reference data in Rome 
might also have caused bias. In another study, neurode-
velopmental outcomes were not different from those of 
healthy matched controls aged 12 and 36 months  [10] . 
Disease-determining parameters were not reported, 
which precludes comparison with our study. 
 Second, professional background may have played a 
role. In Rotterdam, motor function at 24 months was as-
sessed by a pediatric physical therapist, whereas in Rome 
assessments were performed by developmental psycholo-
gists. Since results of our study did not significantly differ 
from the PDI assessed by developmental psychologists in 
a previous study of our group  [11] , we assume that this 
may not fully explain differences in motor function. 
Moreover, this contradicts our assumption that neurode-
velopmental outcome has worsened due to survival of se-
verely ill patients  [2] . 
 Third, center-specific differences may have played a 
role. Although both tertiary intensive care centers have a 
comparable referral area, patients from Rotterdam may 
have been more critically ill than those from Rome (high-
er proportion of large diaphragmatic defects and higher 
patch use). However, SNAP-II scores and observed to ex-
pected lung-head ratio were not significantly different. 
The surgical approach differed, too. Primarily, a thoraco-
scopic approach was performed in more than 50% in 
 Rotterdam versus open surgery in all patients in Rome. A 
randomized controlled trial of open versus thoracoscopic 
repair in CDH concluded that thoracoscopic repair was 
associated with more prolonged and severe intraopera-
tive hypercapnia and acidosis than open surgery  [23] . 
Moreover, only in Rotterdam was ECMO available. Since 
only 6 survivors received ECMO and patient characteris-
tics did not significantly change after exclusion of these 
children, we assume that this hardly contributes to the 
outcome differences. The influence of center-specific dif-
ferences such as surgical care on neurodevelopmental 
outcome remains speculative, but these observations em-
phasize the need for multicenter studies with standard-
ized protocols. Since scores in Rotterdam slowly deterio-
rate at 24 months, and it is known that early adverse de-
velopment in children with major congenital anomalies 
is predictive of development at 5 years  [5] , follow-up was 
planned for patients from Rotterdam. 
 Next to the differences in study design, the fact that 
not every child was tested at both time points could be 
considered a limitation. However, the numbers of drop-
outs were relatively low and the use of linear mixed mod-
els in the analysis over time accounted for missing data, 
provided that these outcomes were missing at random 
 [24] . 
 Interpreting outcomes in the context of international 
multicenter studies is difficult if the follow-up program is 
not standardized. International guidelines on standard-
ization of follow-up programs in CDH, however, are still 
lacking. So far, the international CDH registry  [25] col-
lects only prenatal, perinatal and early postnatal data. We 
recommend setting up standardized follow-up programs 
using population-appropriate reference data and similar 
assessment instruments as well as assessments performed 
by professionals of the same background. In multicenter 
collaboration, video assessments should be included in 
the training sessions. We like to make an appeal for not 
only international standardization of postnatal care, but 
also for follow-up care beyond the neonatal period, as this 
is essential to improve outcome for CDH patients. This 
would require standardization of treatment protocols 
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and decision flowcharts of referring criteria to pediatric 
physical therapists/speech-language pathologists should 
be involved. Moreover, children should be followed up to 
adolescence since deficits may worsen. 
 In conclusion, although most CDH patients have nor-
mal neurodevelopment within the first 2 years of life, they 
are at risk for impaired motor function. Standardization 
of multicenter long-term follow-up programs using stan-
dardized assessment instruments and stratification to ill-
ness severity is necessary to compare neurodevelopmen-
tal outcomes between centers and to evaluate long-term 
effects of interventions.
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